The trajectory of the erectile dysfunction drug presents a challenging picture for those considering investment. While the initial introduction generated significant returns, the end of its intellectual property protection opened the avenue to off-brand competitors, dramatically eroding revenue. This creates a specific dilemma for drug manufacturer

The history of Viagra, and its parent company copyright, presents a intriguing case study for investors. Originally a blockbuster drug, generating billions in revenue , its exclusivity period created a deluge of knock-off medications, significantly impacting its dominance. While certain firms may try to capitalize on related treatments , the presen